Milestone Asset Management LLC Invests $523,000 in Establishment Labs Holdings Inc. $ESTA

Milestone Asset Management LLC bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 12,235 shares of the company’s stock, valued at approximately $523,000.

Several other hedge funds also recently made changes to their positions in ESTA. New York State Common Retirement Fund bought a new position in Establishment Labs in the first quarter worth about $894,000. Rice Hall James & Associates LLC lifted its holdings in Establishment Labs by 7.4% in the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company’s stock worth $33,763,000 after acquiring an additional 56,756 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in shares of Establishment Labs in the 1st quarter worth approximately $81,000. Royce & Associates LP lifted its holdings in shares of Establishment Labs by 82.4% in the 1st quarter. Royce & Associates LP now owns 192,491 shares of the company’s stock worth $7,855,000 after purchasing an additional 86,965 shares during the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Establishment Labs by 28.2% in the 1st quarter. Federated Hermes Inc. now owns 41,937 shares of the company’s stock worth $1,711,000 after purchasing an additional 9,217 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Stock Up 3.3%

Shares of Establishment Labs stock opened at $49.40 on Wednesday. The business’s fifty day moving average price is $42.82 and its two-hundred day moving average price is $39.84. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The company has a market capitalization of $1.43 billion, a P/E ratio of -16.20 and a beta of 0.98. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $54.06.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.80 million. During the same period in the previous year, the firm earned ($0.62) EPS. The firm’s revenue was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ESTA shares. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Establishment Labs in a report on Wednesday, October 8th. Wall Street Zen raised Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Mizuho raised their price target on Establishment Labs from $58.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Finally, Canaccord Genuity Group started coverage on Establishment Labs in a report on Wednesday, August 20th. They issued a “buy” rating and a $60.00 price target on the stock. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.50.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.